Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics


Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): $8.40

-0.49 (-5.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AVDL Stock Price Chart Interactive Chart >

Price chart for AVDL

AVDL Price/Volume Stats

Current price $8.40 52-week high $10.20
Prev. close $8.89 52-week low $1.05
Day low $8.00 Volume 3,928,116
Day high $8.44 Avg. volume 492,811
50-day MA $8.47 Dividend yield N/A
200-day MA $6.61 Market Cap 518.94M

Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) Company Bio


Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products based on its proprietary drug delivery technology for primary care and sterile injectable markets in the United States, France, and Ireland. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. The company was founded in 1990 and is based in Dublin, Ireland.


AVDL Latest News Stream


Event/Time News Detail
Loading, please wait...

AVDL Latest Social Stream


Loading social stream, please wait...

View Full AVDL Social Stream

Latest AVDL News From Around the Web

Below are the latest news stories about AVADEL PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate AVDL as an investment opportunity.

Avadel Pharma enters into royalty agreement with RTW investments for up to $75M

  • Avadel Pharmaceuticals (NASDAQ:AVDL) on Wednesday said it had entered into a royalty agreement to support the potential commercialization of its sleep disorder drug Lumryz.
  • The company said it had entered into a deal with RTW Investments and certain of its affiliates for up to $75M.
  • AVDL is developing Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
  • The company also said that, concurrently, it had extended the maturity of $96.2M of its convertible notes to 2027.
  • “These critical financing activities, including ...

    Seeking Alpha | March 29, 2023

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”). Each ADS represents the right to receive one Ordinary Share. Avadel may, in lieu of ADSs, offer and sell to certain

Yahoo | March 29, 2023

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its entry into a royalty agreement with RTW Investments, LP and certain of its affiliates (“RTW”) for up

Yahoo | March 29, 2023

Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approval decisionDUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ. Through its PLAIR, Avadel is authorized to import unapproved drug

Yahoo | March 22, 2023

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one (1) new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance wit

Yahoo | March 21, 2023

Read More 'AVDL' Stories Here

AVDL Price Returns

1-mo -15.58%
3-mo 17.32%
6-mo 67.66%
1-year 19.66%
3-year -3.67%
5-year 15.23%
YTD 17.32%
2022 -11.39%
2021 20.96%
2020 -11.52%
2019 192.64%
2018 -68.54%

Continue Researching AVDL

Want to see what other sources are saying about Avadel Pharmaceuticals Plc's financials and stock price? Try the links below:

Avadel Pharmaceuticals Plc (AVDL) Stock Price | Nasdaq
Avadel Pharmaceuticals Plc (AVDL) Stock Quote, History and News - Yahoo Finance
Avadel Pharmaceuticals Plc (AVDL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.673 seconds.